
ENROLLED
COMMITTEE SUBSTITUTE
FOR
Senate Bill No. 127



(Senators Tomblin, Mr. President, and Sprouse,



By Request of the Executive)
____________
[Passed April 14, 2001; in effect ninety days from passage.]
____________
AN ACT to amend chapter five of the code of West Virginia, one
thousand nine hundred thirty-one, as amended, by adding
thereto a new article, designated article sixteen-c, relating
to prescription drug cost management; providing legislative
findings and purpose; defining terms; providing for review and
approval of certain contracts by the public employees
insurance agency finance board; authorizing the director of
the public employees insurance agency to execute certain
prescription drug purchasing agreements, to amend existing
contracts and to execute pharmacy benefit manager contracts;
exempting the agreements and contracts from certain purchasing
requirements; requiring an audit and reports; authorizing the
public employees insurance agency director to explore
innovative strategies for managing prescription drug costs;
requiring semiannual report to the joint committee on
government and finance; and providing for termination of
authorizations.
Be it enacted by the Legislature of West Virginia:

That chapter five of the code of West Virginia, one thousand
nine hundred thirty-one, as amended, be amended by adding thereto
a new article, designated article sixteen-c, to read as follows:
ARTICLE 16C. PRESCRIPTION DRUG COST MANAGEMENT ACT.
§5-16C-1. Legislative findings; purpose; short title.

The Legislature finds that the rapidly rising cost of
prescription drugs places an undue financial burden on the state of
West Virginia, the payors and the consumers of prescription drugs.
The purpose of this legislation is to authorize the director of the
public employees insurance agency to act on behalf of specified
agencies, programs and political subdivisions to manage the steady
increase in prescription drug costs, thus benefitting the citizens
and fiscal strength of this state. This article shall be known and
may be cited as the "Prescription Drug Cost Management Act".
§5-16C-2. Definitions.

As used in this article:

(1) "Audit" means a systematic examination and collection of
sufficient, competent evidential matter needed for an auditor to
attest to the fairness of management's assertions in the financial
statements and to evaluate whether management has sufficiently and
effectively carried out its responsibilities and complied with
applicable laws and regulations, conducted by an independent
certified public accountant in accordance with the applicable
statement on standards: Provided, That the report shall include an
incurred-but-not-reported calculation, where available.

(2) "Director" means the director of the public employees
insurance agency created under article sixteen of this chapter.

(3) "Finance board" means the public employees insurance
agency finance board created in section four, article sixteen of
this chapter.

(4) "Pharmacy benefit manager" means an entity that procures
prescription drugs at a negotiated rate under a contract and which
may serve as a third party prescription drug benefit administrator.

(5) "Prescription drug purchasing agreement" means a written
agreement to pool all parties' prescription drug buying power in
order to negotiate the best possible prices and which delegates
authority to negotiate on behalf of the parties to the director.

(6) "Prescription drugs" mean substances recognized as drugs
in the official "United States Pharmacopoeia, official Homeopathic
Pharmacopoeia of the United States or National Formulary", or any
supplement thereto, dispensed pursuant to a prescription issued by
an authorized health care practitioner, for use in the diagnosis,
cure, mitigation, treatment or prevention of disease in a human, as
well as prescription drug delivery systems, testing kits and
related supplies.
§5-16C-3. Finance board responsibilities for review and approval
of certain contracts.

The finance board is responsible for reviewing any proposed
contract authorized by this article before it is executed by the
director of the public employees insurance agency. If the board
determines that the proposed contract meets the requirements of
this article and would assist in effectively managing the costs for
the programs involved and would not result in jeopardizing state
funds or funds due the state, it shall approve the contract and
authorize the director of the public employees insurance agency to execute the contract.
§5-16C-4. Authorization to execute prescription drug purchasing
agreements.

(a) The director may execute, subject to the provisions of
subsections (b), (c) and (d) of this section and as permitted by
applicable federal law, prescription drug purchasing agreements
with:

(1) All departments, agencies, authorities, institutions,
programs, quasipublic corporations and political subdivisions of
this state, including, but not limited to, the children's health
insurance program, the division of corrections, the division of
juvenile services, the regional jail and correctional facility
authority, the workers' compensation fund, state colleges and
universities, public hospitals, state or local institutions such as
nursing homes, veterans' homes, the division of rehabilitation,
public health departments and the bureau of medical services:
Provided, That any contract or agreement executed with or on behalf
of the bureau of medical services shall contain all necessary
provisions to comply with the provisions of Title XIX of the Social
Security Act, 42 U.S.C. §1396 et seq., dealing with pharmacy
services offered to recipients under the medical assistance plan of
West Virginia;
(2) Governments of other states and jurisdictions and their
individual departments, agencies, authorities, institutions,
programs, quasipublic corporations and political subdivisions;

(3) Regional or multistate purchasing alliances or consortia,
formed for the purpose of pooling the combined purchasing power of
the individual members in order to increase bargaining power; and

(4) Arrangements with entities in the private sector,
including self-funded benefit plans, toward combined purchasing of
health care services, health care management services, pharmacy
benefits management services or pharmaceutical products: Provided,
That no private entity may be compelled to participate in the
prescription drug purchasing pool: Provided, however, That the
director may not execute a contract with a private entity without
further enactment of the Legislature specifically authorizing the
agreement.

(b) The finance board shall approve each agreement before it
is executed by the director and the director may not execute any
agreement not approved by the finance board.

(c) The finance board may not approve and the director may not
execute any agreement that does not effectively and efficiently
manage rising drug costs on behalf of the parties to the agreement.

(d) The finance board may not approve and the director may not
execute any agreement that grants the state's credit for the
purchase of prescription drugs by any entity other than this state.
§5-16C-5. Authorization to amend existing contracts.

The director may renegotiate and amend existing prescription
drug contracts to which the public employees insurance agency is a
party for the purpose of managing rising drug costs.
§5-16C-6. Authorization to execute pharmacy benefit management
contract.

The director may negotiate and execute pharmacy benefit
management contracts for the purpose of managing rising drug costs
for this state and all parties which have executed prescription
drug purchasing agreements with the director.
§5-16C-7. Exemption from purchasing division requirements.

The provisions of article three, chapter five-a of this code
do not apply to the agreements and contracts executed under the
provisions of this article, except that the contracts and
agreements shall be approved as to form and conformity with
applicable law by the attorney general.
§5-16C-8. Audit required; reports.

(a) The director shall cause to be conducted an audit of any
funds expended pursuant to any prescription drug purchasing
agreement or pharmacy benefit management contract executed under
the provisions of this article for each fiscal year that the
prescription drug purchasing agreement or pharmacy benefit
management contract is in effect. The director shall submit the
audit to the joint committee on government and finance upon
completion, but in no event later than the thirty-first day of
December after the end of the fiscal year subject to audit.

(b) The director shall provide written notice to the joint
committee on government and finance before executing a prescription
drug purchasing agreement or a pharmacy benefit management contract
or amending an existing prescription drug contract.
§5-16C-9. Innovative strategies.

(a) The director may explore innovative strategies by which
West Virginia may manage the increasing costs of prescription drugs
and increase access to prescription drugs for all of the state's
citizens, including:

(1) Enacting fair prescription drug pricing policies;

(2) Providing for discount prices or rebate programs for
seniors and persons without prescription drug insurance;

(3) Coordinating programs offered by pharmaceutical
manufacturers that provide prescription drugs for free or at
reduced prices;

(4) Requiring prescription drug manufacturers to disclose to
the state expenditures for advertising, marketing and promotion, as
well as for provider incentives and research and development
efforts;

(5) Establishing counter-detailing programs aimed at educating
health care practitioners authorized to prescribe prescription
drugs about the relative costs and benefits of various prescription
drugs, with an emphasis on generic substitution for brand name
drugs when available and appropriate; prescribing older, less
costly drugs instead of newer, more expensive drugs, when
appropriate; and prescribing lower dosages of prescription drugs,
when available and appropriate;

(6) Establishing disease state management programs aimed at
enhancing the effectiveness of treating certain diseases identified
as prevalent among this state's population with prescription drugs;

(7) Studying the feasibility and appropriateness of executing
prescription drug purchasing agreements with large private sector
purchasers of prescription drugs and including those private
entities in pharmacy benefit management contracts;

(8) Studying the feasibility and appropriateness of
authorizing the establishment of voluntary private buying clubs,
cooperatives or purchasing alliances comprised of small businesses
and or individuals for the purpose of purchasing prescription drugs
at optimal prices; and
(9) Other strategies, as permitted under state and federal law, aimed at managing escalating prescription drug prices and
increasing affordable access to prescription drugs for all West
Virginia citizens.

(b) The director shall report to the joint committee on
government and finance on a semi-annual basis regarding activities
and recommendations relating to the mandates of this section.
§5-16C-10. Termination.

The authorizations provided for in this article terminate
pursuant to the provisions of article ten, chapter four of this
code on the first day of July, two thousand five, unless continued
pursuant to the provisions of that article by legislation enacted
prior to the termination.